孕妇呼吸道合胞病毒疫苗的研究进展及接种策略
Research progress and vaccination strategies of respiratory syncytial virus vaccines for pregnant women
摘要
呼吸道合胞病毒(RSV)是导致全球0~1岁婴幼儿,特别是6月龄以下婴幼儿,严重下呼吸道感染及住院的主要病原体。目前尚无获批用于婴幼儿主动免疫的RSV疫苗,仅能通过单克隆抗体为婴幼儿提供保护。因此,通过给妊娠期孕妇接种RSV疫苗,诱导其体内产生抗体并经胎盘转运至胎儿,成为婴儿早期提供被动免疫的重要预防策略。本综述阐述了RSV的发病机制与免疫应答特点,梳理疫苗研发历程中的关键突破与难点,重点基于最新临床试验与上市后监测数据,分析妊娠期接种呼吸道合胞病毒融合前F蛋白疫苗(RSVpreF)的有效性、安全性及免疫原性证据。同时,本文综述对比了世界卫生组织、欧洲药品管理局等主要卫生机构的接种建议与策略差异,并深入探讨了在疫苗认知、全球可及性、长期安全性证据及特殊人群应用等方面面临的挑战与未来研究方向,旨在为临床实践与公共卫生决策提供循证参考。
Respiratory syncytial virus (RSV) is a predominant global pathogen responsible for severe lower respiratory tract infections and hospitalizations in infants, especially those aged under six months. To date, no vaccines have been approved for active immunization against RSV in infant populations, leaving monoclonal antibodies as the primary modality for immediate, direct RSV protection. Maternal vaccination during pregnancy has evolved as a critical passive immunization approach, wherein vaccine-elicited maternal antibodies cross the placenta to confer early-life protection on neonates and young infants. This review elaborates on the pathogenesis of RSV infection and the features of host immune responses to RSV, summarizes key advances and remaining bottlenecks in RSV vaccine development, and focuses on evaluating the efficacy, safety, and immunogenicity of the prefusion F protein-based RSV vaccine (RSVpreF) based on latest clinical trial findings and post-marketing surveillance data. Additionally, it compares RSV vaccination guidelines and strategic recommendations issued by major global health authorities, including the World Health Organization (WHO) and the European Medicines Agency (EMA). This article further discusses persistent challenges and prospective research priorities in this field, covering public awareness of RSV vaccination, global vaccine accessibility, long-term safety profile monitoring, and vaccine applicability in special populations. Collectively, this review aims to provide evidence-based references to guide clinical practice and optimize public health decision-making regarding RSV prevention.
年,卷(期):
2026, 60(10)
在线出版日期:
2026年10月6日